We use cookies for a better user experience. Read our Privacy Policy

I Agree

Pharmaceutical Contract Sales Outsourcing (CSO) Market

Pharmaceutical Contract Sales Outsourcing (CSO) Market (Therapeutic Area: Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Outlook 2031

  • The pharmaceutical contract sales outsourcing (CSO) market in Europe was valued at US$ 2.2 Bn in 2021
  • The market in the region is projected to grow at a CAGR of 7.6% from 2022 to 2031
  • The pharmaceutical contract sales outsourcing (CSO) market in Europe is anticipated to reach more than US$ 4.6 Bn by the end of 2031

Analysts’ Viewpoint on Pharmaceutical Contract Sales Outsourcing (CSO) Market Scenario

Strategies adopted by key players are expected to drive the pharmaceutical contract sales outsourcing (CSO) market in Europe during the forecast period. In September 2020, Eversana Life Science Services, LLC acquired Alkemy Partners, LLC. Alkemy Partners is a consulting firm that provides medical writing, clinical, and market access training solutions for the life sciences industry. CSOs help achieve brand success and secure financial viability of an emerging pharmaceutical company. CSOs have expertise in various areas such as market analysis, different payer access, and targeting analysis that helps pharmaceutical companies surpass their target goals. This factor is likely to propel the pharmaceutical contract sales outsourcing market in Europe during the forecast period.

europe pharmaceutical contract sales outsourcing (CSO) market

Pharmaceutical Contract Sales Outsourcing (CSO) Market Introduction

Under contract with pharmaceutical or biotech businesses, a contract sales organization (CSO) offers various services and solutions pertaining to pharmaceutical marketing and sales activities. Deployment of CSOs is a crucial strategic choice in the dynamic pharmaceutical sector. Medical sales outsourcing is critical for the path to commercialization. It offers qualified teams to design and manage specialized projects when the project requires commercial solutions, such as marketing, sales promotion activities, or training. Sales representatives provide drug information and sales messaging to healthcare professionals through in-person and remote channels. CSO offers complete medical affairs solutions for non-commercial needs, including contract medical science liaisons and medical affairs consulting (MSL).

Increase in R&D and other operating costs in the pharmaceutical industry are inducing medium and large pharmaceutical companies to outsource their sales operations, as it offers cost controls, better results, and flexibility in terms of operations. This is expected to drive the pharmaceutical contract sales outsourcing (CSO) market in Europe during the forecast period. Increase in presence of prominent players in the region, high investment in research & development for vaccines & biologics, and a surge in the number of pharmaceutical companies are other factors that are likely to drive the pharmaceutical contract sales outsourcing (CSO) market in Europe.

Request a sample to get extensive insights into the Pharmaceutical Contract Sales Outsourcing (CSO) Market

Digitalization of Services Provided by CSOs Drives Pharmaceutical Contract Sales Outsourcing (CSO) Market

Improved and advanced services provided by the CSOs, such as in the field of non-personal promotions, are expected to drive the pharmaceutical contract sales outsourcing market share in Europe during the forecast period. Large as well as small pharmaceutical companies are looking for drugs to cost-effectively and rapidly enter their pipelines, and CSOs play an important role in this. Rise in virtual detailing in outsourcing services is increasing dependence on CSO services. A surge in the usage of tele-detailing drives the non-personal promotion of outsourcing. All these advanced functions including salesforce and customer support are well-established in a CSO, which can help the pharmaceutical brand to get market recognition faster.

Cost Control by Emerging Pharmaceutical Companies to Propel Market

Emerging specialty pharma firms have been looking for agreements with established pharmaceutical giants for several years in order to launch their brands. Large pharmaceutical corporations are eager to collaborate because they need medications that can join their pipelines promptly and economically. Deals exist, ranging from selling commercialization rights entirely to licensing products. Working with a CSO enables young pharmaceutical firms to incorporate flexibility into their sales approach from the start.

Emerging businesses can quickly assemble an agile, scalable, and responsive team to meet customer demands with the help of an experienced CSO partner, thus ensuring that key market segments are serviced by the appropriate sales personnel and scaling up or down as the market demands with no negative effects on internal operations.

Increase in Research & Development Costs Boosts Demand for Personal Promotion Services

In terms of service, the pharmaceutical contract sales outsourcing (CSO) market in Europe has been classified into personal promotion, non-personal promotion, and others. The personal promotion segment has been split into promotional sales team, key account management, and vacancy management. The non-personal promotion segment has been segregated into tele-detailing, interactive e-detailing, customer service, medical science liaisons, patient engagement services, and others.

The personal promotion segment is projected to boost the Europe pharmaceutical contract sales outsourcing market size from 2022 to 2031. Significant increase in research & development costs, technological advancements, and product innovations in biologics have prompted several pharmaceutical companies to outsource sales services to CSOs. This propels the personal promotion services segment.

Rise in Prevalence of Cancer to Augment Incremental Opportunities in Oncology

Based on therapeutic area, the pharmaceutical contract sales outsourcing (CSO) market in Europe has been divided into cardiovascular disorders, oncology, metabolic disorders, neurology, orthopedic diseases, infectious diseases, and others. The oncology segment held a major market share in 2021. The segment is likely to expand at a higher CAGR during the forecast period. Increase in the patient population with different types of cancer is expected to drive the segment during the forecast period.

Outlook of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market

The U.K. accounted for the largest share of around 21% of the pharmaceutical contract sales outsourcing (CSO) market in Europe in 2021. The market in the country is projected to grow at a CAGR of 7.6% from 2022 to 2031. Well-established healthcare infrastructure, early adoption of technologically advanced services, and an increase in acceptance and demand for pharmaceutical CSO services are the key factors ascribed to the U.K.’s large market share in 2021.

Rest of Europe is anticipated to be the fastest growing region in Europe during the forecast period, owing to a rise in disease burden leading to an increase in infectious diseases testing, and significant costs associated with commercial activities. The market in Italy and Spain is likely to experience moderate growth in the near future due to developments in pharma sales outsourcing.

Analysis of Key Players in Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market

The pharmaceutical contract sales outsourcing (CSO) market in Europe is consolidated, with the presence of a small number of leading players. Expansion of product portfolios and mergers & acquisitions are the key strategies adopted by the players. Leading and prominent players operating in the pharmaceutical contract sales outsourcing (CSO) market in Europe are Ashfield (UDG Healthcare plc), Syneos Health, IQVIA, Inc., GTS Solution, EVERSANA, MaBiCo, Pharmaforce Ireland, Sales Focus, Inc., Amplity Health, PharmaLex GmbH, Star OUTiCO, and NiSiPharm GmbH.

Request a custom report on Pharmaceutical Contract Sales Outsourcing (CSO) Market

Key Developments in Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market

In March 2021, IQVIA collaborated with Janssen Research & Development on phase 3 COVID-19 vaccine clinical trials. The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of telehealth technologies, virtual oversight, and digital patient engagement strategies.

In February 2021, Ashfield engaged in a partnership with Popit to improve patient adherence. This enabled Ashfield to bring together novel technologies and patient support programs to proactively respond to patients’ needs and tailor their reminders accordingly.

In December 2020, Syneos Health announced the acquisition of Illingworth Research Group. The acquisition adds new scale and capabilities to Syneos Health’s decentralized clinical trial solutions.

In June 2020, PharmaLex GmbH completed the merger with Regulis Consulting Limited (Regulis) in the U.K. to increase its share in the market

In May 2019, Vanguard Pharma expanded its product portfolio to new and exciting parts of the health care business

Each of these players has been profiled in the pharmaceutical contract sales outsourcing (CSO) market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 2.2 Bn

Market Forecast Value in 2031

More than US$ 4.6 Bn

Growth Rate (CAGR)

7.6%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as at regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

Market share analysis by company (2021)

Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Service
    • Personal Promotion
      • Promotional Sales Team
        • Dedicated Sales Team
        • Syndicated Sales Team
      • Key Account Management
      • Vacancy Management
    • Non-personal Promotion
      • Tele-detailing
      • Interactive E-detailing
      • Customer Service
      • Medical Science Liaisons
      • Patient Engagement Services
      • Others (telesampling)
    • Others
  • Therapeutic Area
    • Cardiovascular Disorders
    • Oncology
    • Metabolic Disorders
    • Neurology
    • Orthopedic Diseases
    • Infectious Diseases
    • Others

Countries/Sub-region Covered

  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe

Companies Profiled

  • Ashfield (UDG Healthcare plc)
  • Syneos Health
  • IQVIA Inc.
  • GTS Solution
  • EVERSANA
  • MaBiCo
  • Pharmaforce Ireland
  • Sales Focus, Inc.
  • Amplity Health
  • PharmaLex GmbH
  • Star OUTiCO
  • NiSiPharm GmbH
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the pharmaceutical contract sales outsourcing (CSO) market in Europe in 2021?

The pharmaceutical contract sales outsourcing (CSO) market in Europe was valued at US$ 2.2 Bn in 2021

How big will be the pharmaceutical contract sales outsourcing (CSO) market in Europe in 2031?

The pharmaceutical contract sales outsourcing (CSO) market in Europe is projected to reach more than US$ 4.6 Bn by 2031

What was the CAGR of the pharmaceutical contract sales outsourcing (CSO) market Europe from 2017–2021?

The pharmaceutical contract sales outsourcing (CSO) market in the region grew at a CAGR of 2.7% from 2017 to 2021

What will be the CAGR of the pharmaceutical contract sales outsourcing (CSO) market in Europe during the forecast period (2022–2031)?

The pharmaceutical contract sales outsourcing (CSO) market in Europe is anticipated to grow at a CAGR of 7.6% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in R&D and other operating costs in the pharmaceutical industry

What was the market share of the leading segment of the pharmaceutical contract sales outsourcing (CSO) market in Europe in 2021?

The personal promotion segment held over 60% share of the pharmaceutical contract sales outsourcing (CSO) market in the region in 2021

Which country will account for major share of the market in Europe during the forecast period?

The U.K. is expected to account for major share of the pharmaceutical contract sales outsourcing (CSO) market in the region during the forecast period

Who are the prominent players in the pharmaceutical contract sales outsourcing (CSO) market in Europe?

Ashfield (UDG Healthcare plc), Syneos Health, IQVIA, Inc., GTS Solution, EVERSANA, MaBiCo, Pharmaforce Ireland Ltd., Sales Focus, Inc., Amplity Health, PharmaLex GmbH, Star OUTiCO, and NiSiPharm GmbH

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Europe Healthcare Industry Overview

    5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short /mid / long term impact)

6. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Service, 2017–2031

        6.3.1. Personal Promotion

            6.3.1.1. Promotional Sales Team

                6.3.1.1.1. Dedicated Sales Team

                6.3.1.1.2. Syndicated Sales Team

            6.3.1.2. Key Account Management

            6.3.1.3. Vacancy Management

        6.3.2. Non-personal Promotion

            6.3.2.1. Tele-detailing

            6.3.2.2. Interactive E-detailing

            6.3.2.3. Customer Service

            6.3.2.4. Medical Science Liaisons

            6.3.2.5. Patient Engagement Services

            6.3.2.6. Others

        6.3.3. Other Services

    6.4. Market Attractiveness Analysis, by Service

7. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        7.3.1. Cardiovascular Disorders

        7.3.2. Oncology

        7.3.3. Metabolic Disorders

        7.3.4. Neurology

        7.3.5. Orthopedic Diseases

        7.3.6. Infectious Diseases

        7.3.7. Others

    7.4. Market Attractiveness Analysis, by Therapeutic Area

8. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. Germany

        8.2.2. U.K.

        8.2.3. France

        8.2.4. Italy

        8.2.5. Spain

        8.2.6. Rest of Europe

    8.3. Market Attractiveness Analysis, by Country/Sub-region

9. Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Service, 2017–2031

        9.2.1. Personal Promotion

            9.2.1.1. Promotional Sales Team

                9.2.1.1.1. Dedicated Sales Team

                9.2.1.1.2. Syndicated Sales Team

            9.2.1.2. Key Account Management

            9.2.1.3. Vacancy Management

        9.2.2. Non-personal Promotion

            9.2.2.1. Tele-detailing

            9.2.2.2. Interactive E-detailing

            9.2.2.3. Customer Service

            9.2.2.4. Medical Science Liaisons

            9.2.2.5. Patient Engagement Services

            9.2.2.6. Others

        9.2.3. Other Services

    9.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        9.3.1. Cardiovascular Disorders

        9.3.2. Oncology

        9.3.3. Metabolic Disorders

        9.3.4. Neurology

        9.3.5. Orthopedic Diseases

        9.3.6. Infectious Diseases

        9.3.7. Others

    9.4. Market Attractiveness Analysis

        9.4.1. By Service

        9.4.2. By Therapeutic Area

10. U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Service, 2017–2031

        10.2.1. Personal Promotion

            10.2.1.1. Promotional Sales Team

                10.2.1.1.1. Dedicated Sales Team

                10.2.1.1.2. Syndicated Sales Team

            10.2.1.2. Key Account Management

            10.2.1.3. Vacancy Management

        10.2.2. Non-personal Promotion

            10.2.2.1. Tele-detailing

            10.2.2.2. Interactive E-detailing

            10.2.2.3. Customer Service

            10.2.2.4. Medical Science Liaisons

            10.2.2.5. Patient Engagement Services

            10.2.2.6. Others

        10.2.3. Other Services

    10.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        10.3.1. Cardiovascular Disorders

        10.3.2. Oncology

        10.3.3. Metabolic Disorders

        10.3.4. Neurology

        10.3.5. Orthopedic Diseases

        10.3.6. Infectious Diseases

        10.3.7. Others

    10.4. Market Attractiveness Analysis

        10.4.1. By Service

        10.4.2. By Therapeutic Area

11. France Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Service, 2017–2031

        11.2.1. Personal Promotion

            11.2.1.1. Promotional Sales Team

                11.2.1.1.1. Dedicated Sales Team

                11.2.1.1.2. Syndicated Sales Team

            11.2.1.2. Key Account Management

            11.2.1.3. Vacancy Management

        11.2.2. Non-personal Promotion

            11.2.2.1. Tele-detailing

            11.2.2.2. Interactive E-detailing

            11.2.2.3. Customer Service

            11.2.2.4. Medical Science Liaisons

            11.2.2.5. Patient Engagement Services

            11.2.2.6. Others

        11.2.3. Other Services

    11.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        11.3.1. Cardiovascular Disorders

        11.3.2. Oncology

        11.3.3. Metabolic Disorders

        11.3.4. Neurology

        11.3.5. Orthopedic Diseases

        11.3.6. Infectious Diseases

        11.3.7. Others

    11.4. Market Attractiveness Analysis

        11.4.1. By Service

        11.4.2. Therapeutic Area

12. Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Service, 2017–2031

        12.2.1. Personal Promotion

            12.2.1.1. Promotional Sales Team

                12.2.1.1.1. Dedicated Sales Team

                12.2.1.1.2. Syndicated Sales Team

            12.2.1.2. Key Account Management

            12.2.1.3. Vacancy Management

        12.2.2. Non-personal Promotion

            12.2.2.1. Tele-detailing

            12.2.2.2. Interactive E-detailing

            12.2.2.3. Customer Service

            12.2.2.4. Medical Science Liaisons

            12.2.2.5. Patient Engagement Services

            12.2.2.6. Others

        12.2.3. Other Services

    12.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        12.3.1. Cardiovascular Disorders

        12.3.2. Oncology

        12.3.3. Metabolic Disorders

        12.3.4. Neurology

        12.3.5. Orthopedic Diseases

        12.3.6. Infectious Diseases

        12.3.7. Others

    12.4. Market Attractiveness Analysis

        12.4.1. By Service

        12.4.2. By Therapeutic Area

13. Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Service, 2017–2031

        13.2.1. Personal Promotion

            13.2.1.1. Promotional Sales Team

                13.2.1.1.1. Dedicated Sales Team

                13.2.1.1.2. Syndicated Sales Team

            13.2.1.2. Key Account Management

            13.2.1.3. Vacancy Management

        13.2.2. Non-personal Promotion

            13.2.2.1. Tele-detailing

            13.2.2.2. Interactive E-detailing

            13.2.2.3. Customer Service

            13.2.2.4. Medical Science Liaisons

            13.2.2.5. Patient Engagement Services

            13.2.2.6. Others

        13.2.3. Other Services

    13.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        13.3.1. Cardiovascular Disorders

        13.3.2. Oncology

        13.3.3. Metabolic Disorders

        13.3.4. Neurology

        13.3.5. Orthopedic Diseases

        13.3.6. Infectious Diseases

        13.3.7. Others

    13.4. Market Attractiveness Analysis

        13.4.1. By Service

        13.4.2. By Therapeutic Area

14. Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Service, 2017–2031

        14.2.1. Personal Promotion

            14.2.1.1. Promotional Sales Team

                14.2.1.1.1. Dedicated Sales Team

                14.2.1.1.2. Syndicated Sales Team

            14.2.1.2. Key Account Management

            14.2.1.3. Vacancy Management

        14.2.2. Non-personal Promotion

            14.2.2.1. Tele-detailing

            14.2.2.2. Interactive E-detailing

            14.2.2.3. Customer Service

            14.2.2.4. Medical Science Liaisons

            14.2.2.5. Patient Engagement Services

            14.2.2.6. Others

        14.2.3. Other Services

    14.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        14.3.1. Cardiovascular Disorders

        14.3.2. Oncology

        14.3.3. Metabolic Disorders

        14.3.4. Neurology

        14.3.5. Orthopedic Diseases

        14.3.6. Infectious Diseases

        14.3.7. Others

    14.4. Market Attractiveness Analysis

        14.4.1. By Service

        14.4.2. By Therapeutic Area

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis/Ranking, by Company, 2021

    15.3. Company Profiles

        15.3.1. Ashfield (UDG Healthcare plc)

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Syneos Health

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. IQVIA, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. GTS Solution

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. EVERSANA

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. MaBiCo

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Pharmaforce Ireland Ltd.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Sales Focus, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Amplity Health

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. PharmaLex GmbH

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

        15.3.11. Star OUTiCO

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Company Financials

            15.3.11.3. Growth Strategies

            15.3.11.4. SWOT Analysis

        15.3.12. NiSiPharm GmbH

            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.12.2. Company Financials

            15.3.12.3. Growth Strategies

            15.3.12.4. SWOT Analysis

List of Tables

Table 01: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 02: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 03: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 04: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 05: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 06: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 07: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 08: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 09: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 10: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 11: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 12: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 13: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 14: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 15: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 16: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 17: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 18: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 19: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 20: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 21: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 22: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 23: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 24: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 25: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 26: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 27: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 28: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 29: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 30: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 31: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

Table 32: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031

Table 33: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031

Table 34: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031

Table 35: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031

Table 36: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031

List of Figures

Figure 01: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Service, 2021

Figure 03: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Therapeutic Area, 2021

Figure 04: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Country/Sub-region, 2021

Figure 05: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 06: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 07: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Personal Promotion, 2017–2031

Figure 08: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Non-personal Promotion, 2017–2031

Figure 09: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017–2031

Figure 10: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 11: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area 2022–2031

Figure 12: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Cardiovascular Disorders, 2017–2031

Figure 13: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Oncology, 2017–2031

Figure 14: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Metabolic Disorders, 2017–2031

Figure 15: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Neurology, 2017–2031

Figure 16: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Orthopedic Diseases, 2017–2031

Figure 17: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Infectious Diseases, 2017–2031

Figure 18: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017–2031

Figure 19: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2021 and 2031 

Figure 20: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 21: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 22: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 23: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 24: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 25: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 26: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 27: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 28: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 29: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 30: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 31: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 33: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 34: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 35: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 36: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 38: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 39: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 40: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 41: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 42: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 43: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 44: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 45: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Figure 46: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031

Figure 47: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031

Figure 48: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031

Figure 49: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031

Figure 50: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved